Tag Archives: England

England's Latest Innovation Scorecard: A Patchy Picture

By Leela Barham. A common gripe from those in the pharma industry in England is that even when their products have been found to be cost effective by the National Institute for Health and Care Excellence (NICE) (not always easy to do these days), uptake in the NHS can be ‘low and slow’.  The latest […]
Posted in Europe, Global, Guest Blog, Regulatory | Also tagged , , , , | Leave a comment

The UK's New "Revolutionary" Medicines Optimization Plan

By Leela Barham. The UK’s Royal Pharmaceutical Society has joined forces with a number of other organizations, including the Association of the British Pharmaceutical Industry (ABPI), to issue new guidance on medicines optimization.  Sir Bruce Keogh, Medical Director of NHS England, says it could be revolutionary.
Posted in Europe, Global, Guest Blog, Op-Ed | Also tagged , , , , , | Leave a comment

England's Cancer Drug Fund: An Acid Test for Value Based Pricing

By Leela Barham. England’s Cancer Drugs Fund (CDF) could be in its final financial year, after running in full since April 2011.  The fund covers the cost of cancer treatments either when NICE has said ‘no’, or hasn’t yet come to a view.  Companies can’t circumvent NICE though; if a company was invited to submit […]
Posted in Europe, Global, Guest Blog, Op-Ed, pricing | Also tagged , , , , | Leave a comment

Naughty Localities Need to Obey NICE, or Else!

Like governors in the US vowing to block Medicaid expansion in their home states, local primary care trusts (PCTs) in the UK don’t always follow national guidelines on drug access due to budgetary concerns. But that may change in 2013; according to comments made by Minister David Willetts last month, NHS could face monetary penalties […]
Posted in Agency Insight, Global, healthcare, Legal, Market Access, pricing, Regulatory, Strategy | Also tagged , , , , , , , | Leave a comment
  • Categories

  • Meta